CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase II Study of Subcutaneous Bortezomib in Combination With Chemotherapy (VXLD) for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT01769209
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:37:05.457556+00:00
- Published At
- 2018-10-09T00:00:00+00:00
- Record Updated At
- 2018-11-14
- Results Posted At
- 2018-10-09
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["B-cell Adult Acute Lymphoblastic Leukemia (ALL)", "Ph-positive Adult Acute Lymphoblastic Leukemia (ALL)", "Recurrent Adult Acute Lymphoblastic Leukemia (ALL)", "T-cell Adult Acute Lymphoblastic Leukemia (ALL)"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-11-14"- protocolSection.identificationModule.nctId
"NCT01769209"- protocolSection.identificationModule.officialTitle
"A Phase II Study of Subcutaneous Bortezomib in Combination With Chemotherapy (VXLD) for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2018-10-09"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.